Wednesday , February 24 2021
Home / T. Cowen: Marginal Revolution / Canada and Novavax

Canada and Novavax

Summary:
Canada has made some smart moves with the Novavax vaccine. First, they initiated a rolling review of the Novavax vaccine in late January which suggests that they might authorize the vaccine based on the British trial before the US trial is concluded. The FDA will probably wait until the US trial is concluded. Second, Canada also signed a production agreement to bring some capacity online in Canada, although that will take time. That agreement, however, is on top of an advance purchase of 52 million doses with an option on another 24 million doses. In short, if they act quickly, Canada could approve the Novavax vaccine before the United States and get a jump on its own vaccination efforts. The post Canada and Novavax appeared first on Marginal REVOLUTION.

Topics:
Alex Tabarrok considers the following as important: , ,

This could be interesting, too:

Tyler Cowen writes The demand for crypto

Tyler Cowen writes Personnel economics working in the supermarket

Tyler Cowen writes Texas power cut bleg

Alex Tabarrok writes Myopic Voters and Natural Disaster Policy

Canada has made some smart moves with the Novavax vaccine. First, they initiated a rolling review of the Novavax vaccine in late January which suggests that they might authorize the vaccine based on the British trial before the US trial is concluded. The FDA will probably wait until the US trial is concluded. Second, Canada also signed a production agreement to bring some capacity online in Canada, although that will take time. That agreement, however, is on top of an advance purchase of 52 million doses with an option on another 24 million doses.

In short, if they act quickly, Canada could approve the Novavax vaccine before the United States and get a jump on its own vaccination efforts.

The post Canada and Novavax appeared first on Marginal REVOLUTION.

Alex Tabarrok
Alex Tabarrok is Bartley J. Madden Chair in Economics at the Mercatus Center at George Mason University and a professor of economics at George Mason University. He specializes in patent-system reform, the effectiveness of bounty hunters compared to the police, how judicial elections bias judges, and how local poverty rates impact trial decisions by juries. He also examines methods for increasing the supply of human organs for transplant, the regulation of pharmaceuticals by the FDA, and voting systems.

Leave a Reply

Your email address will not be published. Required fields are marked *